Picture of Sumitomo Pharma Co logo

4506 Sumitomo Pharma Co Income Statement

0.000.00%
jp flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

Annual income statement for Sumitomo Pharma Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

2019
March 31st
2020
March 31st
2021
March 31st
2022
March 31st
2023
March 31st
Period Length:12 M12 M12 M12 M12 M
Source:YuhoYuhoYuhoYuhoYuho
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue459,267482,732515,952560,035555,544
Cost of Revenue
Gross Profit345,714353,687378,307402,919377,050
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses401,383399,493444,728499,801632,523
Operating Profit57,88483,23971,22460,234-76,979
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes65,04683,94777,85182,961-47,920
Provision for Income Taxes
Net Income After Taxes48,62735,91836,82940,600-96,714
Minority Interest
Net Income Before Extraordinary Items
Net Income48,62740,75356,21956,413-74,512
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income48,62740,75356,21956,413-74,512
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS135140164142-150
Dividends per Share